Precision oncology startup 4baseCare, backed by Infosys co-founder Nandan Nilekani’s Fundamentum Partnership, has raised ₹128 crore in fresh funding to accelerate the global expansion of its cancer genomics and artificial intelligence platforms. The investment will support the company’s plans to scale its precision oncology solutions, expand genomic testing laboratories internationally, and strengthen access to personalized cancer care.

The funding will be used to grow 4baseCare’s AI-driven platform, OncoTwin, which helps clinicians analyze genomic data and identify personalized treatment options for cancer patients. The company also plans to expand its network of genomics laboratories across global markets while strengthening its presence in India.

Founded with the mission of making precision oncology more accessible, 4baseCare focuses on addressing a key challenge in cancer care the underrepresentation of Asian and other diverse populations in global genomic datasets. By building population-specific genomic insights, the company aims to improve treatment recommendations and clinical outcomes for patients who may not benefit fully from existing datasets.

A major focus area for the startup is the decentralization of genomic testing infrastructure across India. By bringing advanced molecular diagnostics closer to hospitals, oncologists, and patients, the company seeks to reduce turnaround times and improve access to precision cancer care beyond major metropolitan cities.

Cancer remains one of the leading causes of mortality worldwide, with millions of new cases diagnosed each year. Healthcare experts increasingly view genomics and precision medicine as critical tools in improving early diagnosis, treatment selection, and patient outcomes. AI-powered platforms are also playing a growing role in interpreting complex genomic information and supporting clinical decision-making.

Industry analysts note that investments in precision oncology continue to rise globally as healthcare systems shift toward personalized treatment approaches. The integration of genomics, artificial intelligence, and digital health technologies is expected to transform cancer management over the coming decade.

The latest funding round positions 4baseCare to strengthen its international footprint while advancing its goal of making personalized cancer treatment more inclusive and accessible. As demand for precision oncology solutions grows, the company aims to play a larger role in delivering data-driven cancer care for diverse patient populations worldwide.